title: A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
abstract: This study aimed to calculate the cost-effectiveness of infant pneumococcal vaccination in the Netherlands, using the 13-valent PCV13 vs. the currently used 10-valent PCV10. We adapted a previously published model, using recent estimates of epidemiological and efficacy data. In 12 scenarios, we explored the impact of different assumptions on the incremental cost-effectiveness ratio (ICER) of PCV13 over PCV10.Taking only direct effects on invasive pneumococcal disease into account, PCV13 was not found to be cost-effective at a price difference of €11 per dose. If herd protection, replacement and non-invasive disease were also taken into account, the ICER of PCV13 compared with PCV10 was below €30 000/QALY gained in 11 of 12 scenarios. PCV13 was considered dominant in the primary scenario with a price difference below €2.63 per dose.
authors.affiliation: a PharmacoEpidemiology & PharmacoEconomics (PE2); University of Groningen; Groningen, The Netherlands.
authors.forename: Pepijn
authors.initials: P
authors.lastname: Vemer
authors.forename: Maarten J
authors.initials: MJ
authors.lastname: Postma
mesh_terms: D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D009426:Netherlands / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000191:economics / Q000276:immunology*; D014611:Vaccination / Q000191:economics* / Q000379:methods
chemical_list: C538863:10-valent pneumococcal vaccine; C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines
keywords: Netherlands; PCV; Pneumococcal; cost-effectiveness; infant vaccination; vaccines